How Foundayo Could Boost GLP-1 Patient Adherence

The FDA has approved Foundayo (orforglipron), a once-daily oral medication for chronic weight management.¹ Developed by Eli Lilly and Company, Foundayo is a non-peptide, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. It is indicated for use alongside a reduced-calorie diet and increased physical activity in adults with obesity, or those who are overweight with at least one weight-related comorbid condition.¹

This approval marks a significant regulatory milestone as the first new molecular entity cleared under the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program.¹ The drug’s review was completed in just 50 days, representing the fastest NME approval since 2002.¹

“This approval demonstrates what the FDA can achieve when we eliminate delays and prioritize fast and thorough work from the agency and industry partners,” said FDA Commissioner Martin Makary, MD, MPH, in a release.¹

How Can Foundayo Advance GLP-1 Access and Ease of Use?

A primary focus of the Foundayo launch is addressing the practical barriers that have historically limited the adoption of GLP-1 therapies. While injectable GLP-1 medications have seen high demand, the complexity of administration and strict fasting requirements for existing oral options have posed challenges for long-term adherence. Foundayo distinguishes itself as the only GLP-1 pill that can be taken at any time of day without specific food or water restrictions.²

The clinical community suggests that this flexibility could be a decisive factor in improving patient outcomes. Deborah Horn, DO, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, noted the importance of treatment options that align with patient lifestyles. “People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment,” Horn said.²

According to David A. Ricks, chair and CEO of Eli Lilly, current utilization of GLP-1s remains low relative to the population that could benefit, citing “fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn't serious enough for treatment.”² 

“We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications,” Ricks said.²

What Is the Clinical Efficacy and Adherence Potential of Foundayo?

The FDA’s decision was supported by the ATTAIN clinical trial program, which included more than 4,500 participants.² In the 72-week ATTAIN-1 trial, adults without diabetes who took the highest dose of Foundayo achieved an average weight loss of 27.3 pounds (12.4%), compared to 2.2 pounds (0.9%) in the placebo group.² Beyond weight reduction, the trial demonstrated improvements in cardiovascular risk markers, including systolic blood pressure, triglycerides, and waist circumference.²

Because Foundayo is a tablet taken orally once daily, it eliminates the need for needles, which may encourage higher adherence among patients hesitant about injections. The dosing begins at 0.8 mg and follows a titration schedule, increasing every 30 days—to 2.5 mg, then 5.5 mg—up to a maximum potential dose of 17.2 mg, depending on the patient's tolerability and response.¹ This gradual increase is designed to manage gastrointestinal side effects and help patients stay on the therapy long-term.

How Will Lilly Provide Access to Foundayo?

To facilitate broad access, Eli Lilly announced that Foundayo will be available through LillyDirect with free home delivery starting April 6, 2026.² The company has also introduced a pricing structure aimed at reducing out-of-pocket costs. Eligible patients with commercial insurance may pay as little as $25 per month, while those opting for self-pay can access the medication starting at $149 per month. Additionally, coverage for eligible Medicare Part D individuals is expected to begin in July 2026.²

What Are the Potential Side Effects of Foundayo?

Foundayo’s safety profile is consistent with the GLP-1 receptor agonist class. Common side effects reported in clinical trials include nausea, constipation, diarrhea, vomiting, and abdominal pain.¹ The drug’s labeling includes a boxed warning regarding the risk of thyroid C-cell tumors. Patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 are advised against using the medication. Other warnings include potential risks for pancreatitis, acute gallbladder disease, and hypoglycemia when used with certain other medications.¹

The FDA’s acting CDER director Tracy Beth Høeg, MD, PhD, affirmed the rigor of the review process despite the expedited timeline. “The approval of orforglipron is another example of how the FDA’s CNPV pilot program has been able to more quickly bring effective treatments to Americans. Individuals who are overweight or obese now have an additional option to help with weight loss — a GLP-1 receptor partial agonist pill which does not need to be taken on an empty stomach,” Høeg said.¹

The FDA plans to hold a public meeting on June 4, 2026, to discuss the ongoing implementation and criteria of the CNPV program following this historic first NME approval.

References

• U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. Published April 1, 2026. Accessed April 1, 2026.https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
• Eli Lilly and Company. FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. Published April 1, 2026. Accessed April 1, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill